CBD has very low affinity for CB receptors. It functions being an antagonist or partial antagonist at endogenous cannabinoid receptors (each CB1 and CB2 receptor forms and other G-protein-coupled receptors [GPCRs]) by inhibiting full binding of immediate ligands, and may act principally at allos